中国国际金融股份有限公司 关于北京赛科希德科技股份有限公司 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为 北京赛科希德科技股份有限公司（以下简称"赛科希德"、"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法 （2023 年修订）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求（2022 年修订）》《上海证券交易所上市公司自律监管指引第 11 号— —持续督导》《上海证券交易所科创板股票上市规则（2020 年 12 月修订）》及《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定， 对赛科希德本次使用暂时闲置募集资金进行现金管理事项进行了审慎核查，核查 情况及意见如下： 一、募集资金基本情况 根据中国证监会核发的《关于同意北京赛科希德科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2020]1359 号），公司本次发行人民币普通股（A） 股 20,412,000 股，发行价格为 50.35 元/股，募集资金总额为人民币 102,774.42 万 元，扣除发行费用后的募集资金净额为 92,42 ...

证券代码：688338 证券简称：赛科希德 公告编号：2023-028 北京赛科希德科技股份有限公司 第三届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京赛科希德科技股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日 在公司会议室以现场结合通讯的方式召开第三届董事会第八次会议，本次会议通 知于 2023 年 8 月 4 日以电子邮件形式送达公司全体董事，会议材料均在董事会 会议召开前以电子邮件形式提交全体董事。本次会议应出席的董事 9 人，实际出 席会议的董事 9 人（其中，以通讯方式参会 1 人），会议由董事长吴仕明先生主 持，公司监事及高级管理人员列席了本次会议。本次董事会会议的召开符合有关 法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事审议表决，形成决议如下： 1. 审议通过《关于公司 2023 年半年度报告及其摘要的议案》 表决内容：公司按照相关规定编制了《2023 年半年度报告》以及《2023 ...

中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 北京赛科希德科技股份有限公司（以下简称"赛科希德"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》《证券发行上市保荐业务管理办 法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海 证券交易所科创板股票上市规则》等相关法律、法规和规范性文件的规定，对公 司募投项目延期事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会核发的《关于同意北京赛科希德科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2020]1359 号），同意公司首次公 开发行股票的注册申请。公司本次向社会公开发行人民币普通股（A）股 2,041.20 万股，每股发行价格为人民币 50.35 元，募集资金总额为人民币 102,774.42 万元； 扣除发行费用 10,347.46 万元后，实际募集资金净额为 92,426.96 万元。上述募集 资金全部到账并经容诚会计师事务所（特殊普通合伙）审验并出具《验资报告》 （容诚验字 2 ...

证券代码：688338 证券简称：赛科希德 公告编号：2023-026 北京赛科希德科技股份有限公司 关于募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京赛科希德科技股份有限公司（以下简称"公司"）于2023年8月16日召开 第三届董事会第八次会议、第三届监事会第八次会议，审议通过了《关于公司募 投项目延期的议案》，根据公司募集资金投资项目（以下简称"募投项目"）的实 际建设情况和投资进度，并经过谨慎的研究讨论，拟将募投项目达到预定可使用 状态时间延期至2024年12月，本次募投项目延期仅涉及项目进度的变化，未改变 募投项目投资内容、投资总额、实施主体等，不会对募投项目的实施造成实质性 的影响。公司独立董事发表了明确同意的独立意见，保荐机构中国国际金融股份 有限公司对本事项出具了明确同意的核查意见，该事项无需提交股东大会审议。 现将相关情况公告如下： 公司对募集资金采取了专户存储管理，设立了相关募集资金专项账户。募集 资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账户内。公司 与保荐机构、存 ...

2023 年第一季度报告 证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2023 年第一季度报告 | 加权平均净资产收益率（%） | | 1.75 | 增加 个百分点 | 0.47 | | | | --- | --- | --- | --- | --- | --- | --- | | 研发投入合计 | | 3,811,618.10 | | | 0.37 | | | 研发投入占营业收入的比例（%） | | 5.71 | 减少 | 1.98 | 个百分点 | | | | 本报告期末 | 上年度末 | 本报告期末比上年 度末增减变动幅度 | | | | | | | | (%) | | | | | 总资产 | 1,602,689,410.90 | 1,612,007,4 ...

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 104,114,179.36, with a distributable profit of RMB 346,243,513.10 as of December 31, 2022[5]. - The company plans to distribute a cash dividend of RMB 2.6 per 10 shares, totaling RMB 21,228,480.00, which represents 20.39% of the net profit for the year[5]. - The company's operating revenue for 2022 was CNY 228.81 million, a decrease of 4.63% compared to CNY 239.92 million in 2021[23]. - Net profit attributable to shareholders increased by 6.93% to CNY 104.11 million in 2022, up from CNY 97.37 million in 2021[23]. - The net cash flow from operating activities was CNY 100.56 million, a decline of 6.39% from CNY 107.42 million in 2021[23]. - The company's total assets at the end of 2022 reached CNY 1.61 billion, an increase of 8.64% from CNY 1.48 billion at the end of 2021[23]. - Basic earnings per share rose to CNY 1.28 in 2022, reflecting a growth of 7.56% from CNY 1.19 in 2021[24]. - The company's total revenue for the year reached ¥228,222,764.00, representing a 62.37% increase compared to the previous year[98]. - The sales revenue from coagulation products increased by 72.19% year-on-year, amounting to ¥131,736,202.93[97]. Research and Development - The company is investing in R&D, allocating 150 million RMB towards the development of new technologies and products[15]. - The R&D expenditure as a percentage of operating revenue increased to 7.40% in 2022, up from 6.34% in 2021[24]. - The company invested ¥16,938,833.60 in R&D in 2022, an increase of 11.40% year-on-year[36]. - The company has 21 ongoing R&D projects and has obtained multiple medical device registration certificates and patents during the reporting period[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 32 patents, of which 10 are invention patents[50]. - The company is actively developing new diagnostic products, including lupus anticoagulant testing kits, with several projects in the clinical trial phase[61]. - The company has made significant advancements in the development of monoclonal antibodies for D-Dimer detection, which will improve diagnostic accuracy[73]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[15]. - Market expansion plans include entering two new international markets by the end of the next fiscal year[15]. - The company is considering strategic acquisitions to enhance its product offerings and market presence[15]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[15]. - The company plans to enhance customer acquisition for coagulation products to stabilize revenue amidst declining demand for other products[98]. - The company is focusing on expanding its market presence through the introduction of new products and technologies, aiming for increased competitiveness in the medical device sector[75]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[15]. - The company aims to reduce operational costs by 8% through efficiency improvements in the supply chain[147]. - The operating cost was ¥86,177,055.03, a decrease of 10.08%, with the main business operating cost at ¥85,870,046.34, down 9.67%[94]. - The total gross margin for the year was 62.37%, with a year-on-year decrease of 4.27%[98]. Governance and Compliance - The company maintains a robust governance structure, ensuring compliance with laws and regulations while protecting shareholder rights[133]. - The company emphasizes transparent communication with investors and stakeholders, ensuring timely and accurate information disclosure[136]. - The company’s governance practices comply with relevant laws and regulations, ensuring the legality and validity of shareholder meeting resolutions[140]. - The company has not faced any major legal or regulatory discrepancies in its governance practices[137]. Environmental and Social Responsibility - The company is committed to sustainable development and environmental protection, implementing practices to reduce waste and promote green initiatives[188]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[193]. - The company operates in compliance with environmental regulations, ensuring that wastewater, noise, and solid waste are properly managed[200]. - The company emphasizes sustainable development while protecting the rights of shareholders, creditors, and employees[190]. Human Resources - The number of R&D personnel increased to 48, representing 17.58% of the total workforce, up from 40 and 15.04% respectively in the previous period[80]. - Total compensation for R&D personnel reached 946.14 million, compared to 809.33 million in the prior period[80]. - The company has a comprehensive compensation policy that includes monthly salaries, year-end bonuses, and various allowances, ensuring internal equity and external competitiveness[176]. - The average salary of core technical personnel was reported at 826.42, indicating a competitive compensation structure within the industry[145].

证券代码：688338 证券简称：赛科希德 公告编号：2023-016 北京赛科希德科技股份有限公司 关于召开2022年度暨2023年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京赛科希德科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日在上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有 限公司 2022 年年度报告》及《北京赛科希德科技股份有限公司 2023 年第一季度 报告》，为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度 经营成果、财务状况，公司计划于 2023 年 4 月 28 日 上午 10:00-11:00 举行 2022 年度暨 2023 年第一季度业绩暨现金分红说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范 ...

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 2022 年第三季度报告 证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1 / 17 2022 年第三季度报告 | 基本每股收益（元 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 0.38 | 22.58 | | 0.96 | | | 17.07 | | /股） | | | | | | | | | 稀释每股收益（元 | 0.38 | 22.58 | | 0.96 | | | 17.07 | | /股） | | | | | | | | | 加权平均净资产收 | 2 ...

2022 年第三季度报告 证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 58,023,416.21 | 8.53 | 164,245,829.26 | 0.06 | | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2022 was ¥106,222,413.05, a decrease of 4.04% compared to ¥110,690,541.41 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥47,450,850.29, an increase of 13.72% from ¥41,724,265.86 in the previous year[21]. - The net cash flow from operating activities was ¥33,151,262.89, down 9.99% from ¥36,829,455.81 in the previous year[21]. - The gross margin for the first half of 2022 was reported at 60%, a slight improvement from 58% in the same period last year[1]. - Basic earnings per share for the reporting period increased by 13.73% to CNY 0.58 compared to CNY 0.51 in the same period last year[22]. - The company's operating costs decreased by 8.23% to CNY 41.02 million, primarily due to the decline in operating revenue[81]. - The total revenue for the first half of 2022 reached CNY 94,993,600, with a net profit of CNY 69,431,028, representing a significant increase compared to the previous period[57]. Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on innovative diagnostic technologies[1]. - The total R&D investment for the period was ¥8,133,897.23, a decrease of 2.48% compared to the previous year[50]. - Research and development expenses for the first half of 2022 totaled ¥8,133,897.23, accounting for 7.66% of operating revenue[70]. - The company has established a research and development team dedicated to continuous innovation in the thrombus and hemostasis diagnostic field, ensuring a robust pipeline of new products[43]. - The number of R&D personnel increased to 43, representing 16.35% of the total workforce, compared to 39 and 15.29% respectively in the same period last year[60]. - The company holds 30 patents, including 9 invention patents, and has developed a core technology cluster covering five key areas related to blood rheology and coagulation diagnostics[61]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product portfolio and market reach[1]. - The company is focused on maintaining shareholder confidence through strict adherence to share lock-up commitments[107]. - The company is conducting research on the quantification of low molecular weight heparin, which will aid in drug dosage adjustments for patients[56]. - The company aims to meet the increasing demand for high-end automatic coagulation analyzers in tertiary hospitals[53]. Risks and Challenges - The management highlighted potential risks related to supply chain disruptions, which could impact future performance[1]. - The ongoing COVID-19 pandemic has impacted the company's main business, leading to a significant reduction in diagnostic activities in some regions[67]. - The company faces risks related to reliance on foreign suppliers for key raw materials, which could impact production if supply issues arise[75]. - The company is exposed to intensified market competition in the thrombus and hemostasis market due to the entry of more competitors and improvements in existing competitors' technology and service capabilities[76]. Environmental and Compliance - The company has implemented environmental management standards and procedures to ensure compliance with environmental regulations[94]. - The company’s wastewater treatment facilities recycle cleaning wastewater for toilet flushing, ensuring minimal environmental impact[95]. - The company’s production operations are compliant with national environmental laws, with no administrative penalties for violations during the reporting period[99]. - The company has committed to a stable profit distribution mechanism, detailing conditions and proportions for cash dividends and stock dividends in its profit distribution policy[170]. Shareholder Commitments and Governance - The company confirmed the fulfillment of various commitments made by major shareholders and management, with a focus on share lock-up periods and compliance with regulations[102]. - The company has established a long-term commitment to avoid competition with its major shareholders during their control period[104]. - The company has outlined a commitment to maintain compliance with regulations regarding related party transactions, ensuring transparency and accountability[104]. - The company will ensure that newly appointed non-independent directors and senior management sign a commitment regarding stock price stabilization measures[154]. Investment and Financial Management - The company raised a total of CNY 1,027,744,200.00 from its initial public offering, with a net amount of CNY 924,269,637.22 after deducting issuance costs[187]. - The company has approved the use of up to RMB 730 million of idle raised funds for cash management, ensuring it does not affect project construction and normal operations[191]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments[182]. - The company will implement stock price stabilization measures if the average closing price is below the latest audited net asset value per share for 20 consecutive trading days[153].